Form 4: West Pharmaceutical Services Insider Trading Update
Statement of Changes in Beneficial Ownership
Chad Winters, VP and Chief Accounting Officer of West Pharmaceutical Services, reports transactions involving common stock and stock options.
Summary
- Chad Winters, VP and Chief Accounting Officer at West Pharmaceutical Services Inc. (WST), reported transactions on April 27, 2026.
- He acquired 896 shares of common stock at a weighted average price of $173.22 per share.
- He also disposed of 896 shares of common stock at a weighted average price of $300.6688 per share.
- Following these transactions, Winters beneficially owns 1,522.81 shares of common stock directly.
- Additionally, Winters exercised stock options to acquire 896 shares of common stock at an exercise price of $173.22 per share.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it represents routine insider transactions rather than significant strategic shifts or performance indicators.
Positives
- Acquisition of 896 shares of common stock at $173.22 per share, indicating continued investment in the company.
- Exercise of stock options, potentially realizing gains from previous compensation awards.
Negatives
- Disposal of 896 shares of common stock at a higher price ($300.6688) than the acquisition price ($173.22), suggesting a profitable sale for the reporting person.
Future Outlook
No specific future outlook or guidance is provided in this Form 4 filing, which details past transactions.
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and provide transparency into the trading activities of company executives and significant shareholders. These filings are crucial for investors seeking to understand management's confidence in the company's prospects.
Stakeholder Impact
- Shareholders: The filing provides transparency into insider trading activity, which can inform investor sentiment. The sale of shares by an executive might be interpreted in various ways, but in this case, it appears to be a profitable exercise of options.
- Employees: The exercise of stock options by management can be seen as a positive indicator of the company's performance, potentially aligning with employee stock purchase plans or options.
Key Dates
| Date | Description |
|---|---|
| 02/18/2020 | Date of stock option award grant. |
| 02/18/2021 | First vesting date for stock option award. |
| 04/27/2026 | Date of reported transactions (acquisition and disposal of common stock, exercise of stock options). |
| 04/29/2026 | Date of signature on the filing. |
Keywords
Form 4, Insider Trading, West Pharmaceutical Services, WST, Stock Options, Beneficial Ownership, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.